However, HER2+/HR+ breast cancer was less endocrine sensitive and more aggressive and had worse prognosis compared with HR+/HER2-breast cancer (Lipton et al., 2002; De Laurentiis et al., 2005; Dowsett et al., 2008). The gene discussed is ERBB2; the disease is breast carcinoma.